Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration has
granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Application for Amlodipine Besylate and Benazepril Hydrochloride
Capsules, 2.5 mg (base)/10 mg, 5 mg (base)/10 mg, 5 mg (base)/20 mg and 10 mg (base)/20 mg.
Amlodipine Besylate and Benazepril Hydrochloride Capsules are indicated
for the treatment of hypertension. They are the generic version of
Novartis' Lotrel(R) Capsules, which had annual U.S. sales of approximately
$1.3 billion for the 12 months ending March 31, 2006.
Mylan Laboratories Inc. is a leading pharmaceutical company with three
principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets
and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit mylan/.
Mylan Laboratories Inc.
mylan/